Nodules hypodermiques sarcoïdosiques au cours d'une hépatite virale C traitée par Interféron alpha 2 b

Blum, Laurent; Serfaty, Lawrence; Wattiaux, M. J.; Picard, O; Cabané, J.; Imbert, JC

doi:10.1016/s0248-8663(05)80273-5

Cited by 29 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In certain individuals, IFN-induced sarcoidosis appears to be self-limiting, and regresses without disontinuation of the IFN therapy. 10 In all of the reported cases, the putative induced sarcoidosis or recurrent sarcoidosis in the patients regressed after discontinuation of the IFN, with or without the addition of steroid therapy.…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Reactivation of sarcoidosis during interferon therapy

Yong

Srinivas

et al. 2002

J Gastroenterol

View full text Add to dashboard Cite

The exacerbation of a co-existing autoimmune disease is often a concern for physicians who use immunomodulating agents for the treatment of a concomitant process. As physicians begin to treat chronic hepatitis C more often and more aggressively, this potential problem with occur more frequently. Herein we reported a case of reactivation of sarcoidosis occurring during the treatment of chronic hepatitis C, and we present a literature review of other centers' experiences with this problem. Depending upon the severity of the exacerbation and the type of organ involvement, reactivation of sarcoidosis may require discontinuation of the interferon therapy, with or without the use of additional steroids. The majority of patients, however, do not require the use of steroids. Interestingly, continuation of the interferon therapy in the presence of a mild-to-moderate exacerbation of sarcoidosis may be safe in a minority of patients with noncritical organ involvement.

show abstract

Section: Discussionmentioning

confidence: 91%

“…Blum et al 10 reported a patient who developed skin and lung nodules after being treated with IFN (3 MU three times per week) for HCV-associated liver disease. However, in this patient, the IFN was continued and all of the old nodules regressed, but new lesions appeared in other places.…”

Section: Literature Reviewmentioning

confidence: 99%

Reactivation of sarcoidosis during interferon therapy

Yong

Srinivas

et al. 2002

J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…5 This may explain why only ten cases of IFN-a-induced sarcoidosis were published between 1993 and 1999; while in the last seven years, coinciding with the generalized use of combination therapy, the number of cases reported has increased four-fold. 6 To our knowledge, the first association between sarcoidosis and CHC was reported in 1993 by Blum et al 40 and was directly related to the onset of IFN-a therapy. Since then, the number of cases reported annually has increased significantly, suggesting a closer association than previously suspected.…”

Section: Discussionmentioning

confidence: 96%

Development of Sarcoidosis Following Completion of Treatment for Hepatitis C with Pegylated Interferon- 2a and Ribavirin: A Case Report and Literature Review

Gayet

Plaisance²,

Bergmann³

et al. 2010

Clinical Medicine & Research

View full text Add to dashboard Cite

“…L'élargissement des indications de l'interféron, notamment pour le traitement des hépatites virales est marqué par l'augmentation des cas rapportés de sarcoïdose dans ces conditions. Blum et al [2] ont décrit en 1993 une première observation de sarcoïdose induite par l'interféron prescrit pour le traitement d'une hépatite virale C chronique. La plus grande utilisation de l'interféron et surtout de sa forme pégylée dans le traitement des hépatites virales chroniques est à l'origine de l'augmentation du nombre de cas [3].…”

Section: Discussionunclassified